Overview

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of Abraxane and Carboplatin together will improve the chances of controlling recurrent ovarian/fallopian tube/peritoneal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Southeastern Gynecologic Oncology
Collaborator:
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel